Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $927,520.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Thursday, July 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $81.17, for a total transaction of $649,360.00.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $115.18 on Friday. The stock has a market cap of $12.86 billion, a P/E ratio of -26.91 and a beta of 0.97. The firm has a fifty day moving average price of $89.12 and a 200 day moving average price of $76.38. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter last year, the firm posted ($0.70) EPS. Sell-side analysts expect that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Institutional Trading of Vaxcyte

Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in shares of Vaxcyte by 12.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 481,119 shares of the company’s stock worth $30,214,000 after acquiring an additional 52,005 shares during the period. Vestal Point Capital LP acquired a new stake in shares of Vaxcyte in the 4th quarter worth $32,970,000. Harbor Capital Advisors Inc. lifted its stake in shares of Vaxcyte by 392.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock worth $3,046,000 after acquiring an additional 32,149 shares during the period. TD Asset Management Inc lifted its stake in shares of Vaxcyte by 10.5% in the 4th quarter. TD Asset Management Inc now owns 167,036 shares of the company’s stock worth $10,490,000 after acquiring an additional 15,890 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after acquiring an additional 498,359 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Mizuho upped their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Bank of America upped their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. BTIG Research upped their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Finally, Needham & Company LLC upped their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.